Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial
Mona Boaz(Wolfson Medical Center), Manfred S. Green(University of Haifa), M Fainaru(Tel Aviv University), Talia Weinstein(Rabin Medical Center), Adrian Iaina(Tel Aviv Sourasky Medical Center), Shmuel Smetana(Wolfson Medical Center), Uzi Gafter(Tel Aviv University), Zipora Matas(Laboratoire de Biochimie), Aaron Knecht(Sheba Medical Center), D. Brunner(Wolfson Medical Center), Yehoshua Weissgarten(Assaf Harofeh Medical Center)
Cited by 1,027
Related Papers
The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations
|Journal of the American College of Cardiology|2000|729
The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study
|Journal of the American College of Cardiology|2001|645
Altered renal lipid metabolism and renal lipid accumulation in human diabetic nephropathy
|Journal of Lipid Research|2013|627
Randomised crossover trial of naltrexone in uraemic pruritus
|The Lancet|1996|298